Review of naloxone safety for opioid overdose: Practical considerations for new technology and expanded public access

Therapeutic Advances in Drug Safety

Volumn 6, Issue 1, 2015, Pages 20-31

  Wermeling, Daniel P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

antidote; drug delivery systems; naloxone; opioid; overdose

Indexed keywords

NALOXONE; NOSE SPRAY; OPIATE;

AGGRESSIVENESS; AGITATION; CONFUSION; CONVULSION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; ELEVATED BLOOD PRESSURE; GRAND MAL EPILEPSY; HALLUCINATION; HEART ARREST; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTHERMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; INJECTION SITE REACTION; LUNG EDEMA; NAUSEA; OPIOID OVERDOSE; PARESTHESIA; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEIZURE; SHIVERING; SIDE EFFECT; SWEATING; TACHYCARDIA; TONIC CLONIC SEIZURE; TREMOR; VOMITING; WITHDRAWAL SYNDROME;

EID: 84961288180     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614564776     Document Type: Review

References (48)

1. Bailey A. Wermeling D. (2014) Naloxone for opioid overdose prevention: pharmacists role in community based practice settings. Ann Pharmacother 48: 601–606.
2. Bailey J. Campagna E. Dart R. (2009) The under recognized toll of prescription opioid abuse on young children. Ann Emerg Med 53: 419–424.
3. Barton E. Colwell C. Wolfe T. Fosnocht D. Gravitz C. Bryan T. (2005) Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med 29: 265–271.
4. Barton E. Ramos J. Colwell C. Benson J. Baily J. Dunn W. (2002) Intranasal administration of naloxone by paramedics. Prehosp Emerg Care 6: 54–58.
5. Belz D. Lieb J. Rea T. Eisenberg M. (2006) Naloxone use in a tiered-response emergency medical services system. Prehosp Emerg Care 10: 468–471.
6. Bond G. Woodward R. Ho M. (2012) The growing impact of pediatric pharmaceutical poisoning. J Pediatr 160: 265–270.
7. Boyer E. (2012) Management of opioid analgesic overdose. N Engl J Med 367: 146–155.
8. Buajordet I. Næss A. Jacobsen D. Brørs O. (2004) Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med 11: 19–23.
9. Bunn T. Slavova S. (2012) Drug overdose morbidity and mortality in Kentucky, 2000–2010. Kentucky Injury and Prevention Center.
10. Cantwell K. Dietze P. Flander L. (2005). The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the pre-hospital setting. Resuscitation 65: 315–319.
11. Costantino H. Illum L. Brandt G. Johnson P. Quay S. (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337: 1–24.
12. Davis C. Webb D. Burris S. (2013) Changing Law from Barrier to Facilitator of Opioid OVerdose Prevention. J Law Med Ethics 41(Suppl. 1): 33–36.
13. Doe-Simkins M. Walley A. Epstein A. Moyer P. (2009) Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 99: 788–791.
14. Dowling J. Isbister G. Kirkpatrick C. Naidoo D. Graudins A. (2008) Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 30: 490–496.
15. Goodman L. Gilman A. (2001) Goodman and Gilman–s The Pharmacologic Basis of Therapeutics, 10th edn. New York: McGraw-Hill.
16. Hasegawa K. Brown D. Tsugawa Y Camargo C. (2014) Epidemiology of emergency department visits for opioid overdose: A population-based study. Mayo Clin Proc 89: 461–471.
17. Havens J. Walker R. Leukefeld C. (2007) Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 87: 98–102.
18. Hewlett L. Wermeling D. (2013) Survey of naloxone legal status in opioid overdose prevention. J Opioid Mgmt 9: 369–377.
19. Hospira (2006) Naloxone hydrochloride injection solution prescribing information. Hospira, Inc.
20. IMS (2001) Naloxone hydrochloride injection prescribing information. International Medication Systems, Limited.
21. Jones C. Paulozzi L. Mack K. (2014) Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse – related emergency department visits and drug-related deaths – United States, 2010. CDC MMWR 63(40): 881–885.
22. Kaleo (2014) Evzio™ prescribing information. Kaleo, Inc.
23. Kelly A. Kerr D. Dietze P. Patrick I. Walker T. Koutsogiannis Z. (2005) Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust 182: 24–27.
24. Kerr D. Dietze P. Kelly A. (2008) Intranasal naloxone for the treatment of suspected heroin overdose. Addiction 103: 379–386.
25. Kerr D. Kelly A. Dietze P. Jolley D. Barger B. (2009) Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 104: 2067–2074.
26. Lancet (2013) Editorial: The lethal burden of drug overdose. Lancet 382: 833.
27. Mack K. (2013) Drug-induced deaths – United States, 1999–2010. MMWR 62(03): 161–163.
28. Martindale Pharma (2014) Prenoxad injection. http://www.martindalepharma.co.uk/news/martindale-pharma-launches-prenoxad-injection-for-the-emergency-treatment-of-opioid-overdose/ (accessed 1 November 2014).
29. Merlin M. Saybolt M. Kapitanyan R. Alter S. Jeges J. Lui J. (2010) Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med 28: 296–303.
30. Ngai S. Berkowitz B. Yang J. Hempstead J. Spector S. (1976) Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 44: 398–401.
31. Osterwalder J. (1996) Naloxone - for intoxications with intravenous heroin and heroin mixtures – harmless of hazardous? A prospective clinical study. Clin Toxicol 34: 409–416.
32. Robertson T. Hendey G. Stroh G. Shalit M. (2009) Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care 13: 512–515.
33. Rosen L. Khan D. Warner M. (2013) Trends and geographic patterns in drug-poisoning death rates in the US, 1999–2009. Am J Prev Med 45: e19–e25.
34. Shah N. Lathrop S. Reichard R. Landen M. (2007) Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addiction 103: 126–136.
35. Sporer K. Firestone J. Isaacs S. (1996) Out-of-hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med 3: 660–667.
36. Sporer K. Kral A. (2007) Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 49: 172–177.
37. SAMHSA (2013) SAMHSA Opioid Overdose Prevention Toolkit. Rockville, MD: Substance Abuse and Mental Health Administration.
38. Toblin R. Paulozzi L. Logan J. Hall A. Kaplan J. (2010) Mental illness and psychotropic use among prescription drug overdose deaths: a medical examiner chart review. J Clin Psychiatry 71: 491–496.
39. Vilke G. Buchanan J. Dunford J. Chan T. (1999) Are heroin overdose deaths related to patient release after prehospital treatment with naloxone? Prehosp Emerg Care 3: 183–186.
40. Vilke G. Sloane C. Smith A. Chan T. (2003) Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med 10: 893–896.
41. Walley A. Doe-Simkins M. Quinn E. Pierce C. Xuan Z. Ozonoff A. (2013a) Opioid overdose prevention with intranasal naloxone among people who take methadone. J Sub Abuse Treat 44: 241–247.
42. Walley A. Xuan Z. Hackman H. Quinn E. Doe-Simkins M. Sorensen A. (2013b) Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 346: f174.
43. Wanger K. Brough L. Macmillan I. Goulding J. MacPhail I. Christenson J. (1998) Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med 5: 293–299.
44. Warner M. Chen L. Makuc D. Anderson R. Miniño A. (2011) Drug poisoning deaths in the United States, 1980–2008. NCHS data brief, no. 81. Hyattsville, MD: National Center for Health Statistics.
45. Wermeling D. (2012) A response to the opioid overdose epidemic: naloxone nasal spray. Drug Del Trans Res 3: 63–74.
46. Wheeler E. Davidson P. Jones T. (2012) Community-based opioid overdose prevention programs providing naloxone – United States, 2010. MMWR 61(06): 101–105.
47. Wunsch M. Nakamoto K. Behonick G. Massello W. (2009) Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 18: 5–14.
48. Yealy D. Paris P. Kaplan R. Heller M. Marini S. (1990) The safety of prehospital naloxone administration by paramedics. Ann Emerg Med 19: 902–905.